понедельник, 11 апреля 2016 г.

The History of HGH (Human Growth Hormone)

The History of HGH (Human Growth Hormone)

Growth hormone deficiency causes reduction in the growth rate of the human body. It reduces cell reproduction and regeneration in its victims, whether they are humans or animals. This issue arises mostly in older people and leaves the victim feeling the effects of aging.

In the past, physicians treated this deficiency with the help of bovine growth hormone [rBGH] purification treatment. In the 20th century, they used bovine in its pure form to treat type-1 diabetes patients. This treatment was similar to the human metabolic system, yet, it was not the same as the human requirement. The structure of the bovine somatotropin molecule is different from human growth hormone; thus, it failed to function properly for the human body. Medical science continued searching for a growth supplement. 

This made humankind search for a new treatment for growth hormone deficiency. Their search first became fruitful in 1958, when they made the first successful treatment of human growth hormone. An endocrinologist, whose name was Maurine Raben and who belonged to Tufts University School of Medicine in Boston, Massachusetts, first extracted growth hormone from the pituitary glands of an autopsied body. The news of this success became public in a short period of time, and endocrinologists started to acquire the pituitary glands of autopsied cadavers. This treatment was successful, because it matched the human requirement, since they had extracted it from a human body.

The 1960’s shows more progress in this regard. The U.S National Institute of Health established an organization, so as to regulate supply and demand of cadaver-Growth Hormone. They named this organization the National Pituitary Agency. This organization facilitated the medical community by establishing mass purification of cadaver-GH. Other countries also joined the race of new growth hormone treatment. At first, the doctors did not open this treatment to every individual. They provided it to patients, especially children, who had a marked deficiency of it and who were smaller than a certain height. This all made cadaver-Growth Hormone treatment available to only a small number of patients.

The next step towards advanced human growth hormone was the introduction of Crescormon, the first commercially available GH product. This step made the treatment available to a wider range of patients suffering from human growth hormone deficiency. However, the government had put a stop on this treatment due to the side effects it caused. In 1985, the medical community first diagnosed the signs of Creutzfeldt - Jakob disease [CJD] in individuals who were cadaver GH treated. Later, they found that this disease was common in individuals who had received Growth Hormone treatment earlier in their life.

This cancellation of treatment resulted in the development of a new kind of hormone. An American pharmaceutical company joined hands with the former producer of Crescormon to produce the first synthetic growth hormone. This growth hormone was famous as recombinant human growth hormone (rhGH). Production of this hormone used a process which is referred to as Inclusion Body technology. They named it Somatrem. They further developed the process of somatrem into Protein Secretion technology. Now-a-days, this process is most commonly used for the production of human growth hormones. The hormone result from this technology is called Somatropin. Since then, many nutritional supplements have been created to simulate an anti-aging hormone.*